These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C; Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588 [TBL] [Abstract][Full Text] [Related]
5. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. Huber R; Schlodder D; Effertz C; Rieger S; Tröger W BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036 [TBL] [Abstract][Full Text] [Related]
6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ Oncologist; 2012; 17(1):13. PubMed ID: 22210086 [TBL] [Abstract][Full Text] [Related]
9. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963 [TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412 [TBL] [Abstract][Full Text] [Related]
12. Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. Davis D; Seely D; Morash C; Armstrong J; Meng M; Lowe P; Kogan M Altern Ther Health Med; 2023 May; 29(4):6-17. PubMed ID: 36933241 [TBL] [Abstract][Full Text] [Related]
13. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Tröger W; Galun D; Reif M; Schumann A; Stanković N; Milićević M Dtsch Arztebl Int; 2014 Jul; 111(29-30):493-502, 33 p following 502. PubMed ID: 25142075 [TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Kelter G; Schierholz JM; Fischer IU; Fiebig HH Anticancer Res; 2007; 27(1A):223-33. PubMed ID: 17352237 [TBL] [Abstract][Full Text] [Related]
15. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396 [TBL] [Abstract][Full Text] [Related]
16. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. Kümler I; Sørensen PG; Palshof J; Høgdall E; Skovrider-Ruminski W; Theile S; Fullerton A; Nielsen PG; Jensen BV; Nielsen DL Cancer Chemother Pharmacol; 2019 Jan; 83(1):169-178. PubMed ID: 30406838 [TBL] [Abstract][Full Text] [Related]
17. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F Evid Based Complement Alternat Med; 2014; 2014():236310. PubMed ID: 24955100 [TBL] [Abstract][Full Text] [Related]
18. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study. Pelzer F; Tröger W; Nat DR J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950 [TBL] [Abstract][Full Text] [Related]
19. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612 [TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]